Abstract
The antihypertensive efficacy and tolerability profiles of the selective AT1 receptor antagonists telmisartan and losartan were compared with placebo in a 6-week, multinational, multicentre, randomised, double-blind, double-dummy, parallel-group study of 223 patients with mild-to-moderate hypertension, defined as clinic diastolic blood pressure (DBP) ⩾95 and ⩽114 mm Hg, clinic systolic blood pressure (SBP) ⩾140 and ⩽200 mm Hg, and 24-h ambulatory DBP ⩾85 mm Hg. After a 4-week single-blind placebo run-in, eligible patients were randomised to receive telmisartan 40 mg, telmisartan 80 mg, losartan 50 mg, or placebo. Ambulatory blood pressure monitoring (ABPM) after 6 weeks of double-blind therapy showed that all active treatments produced significant (P < 0.01) reductions from baseline in 24-h mean sbp and dbp compared with placebo. during the 18-to-24 h period after dosing, the reductions in sbp/dbp with telmisartan 40 mg (10.7/6.8 mm hg) and 80 mg (12.2/7.1 mm hg) were each significantly (P <0.05) greater than those observed for losartan 50 mg (6.0/3.7 mm hg), and losartan was no better than placebo. also for the 24-h mean blood pressure, telmisartan 40 mg and 80 mg were significantly (P< 0.05) better than losartan 50 mg. compared with losartan, telmisartan 80 mg produced significantly (P < 0.05) greater reductions in both sbp and dbp during all monitored periods of the 24-h period, while telmisartan 40 mg produced significantly greater reductions in sbp and dbp in the night-time period (10.01 pm to 5.59 am) (P < 0.05) and in dbp in the morning period (6.00 am to 11.59 am) (P < 0.05). all treatments were comparably well tolerated. telmisartan 40 mg and 80 mg once daily were effective and well tolerated in the treatment of mild-to-moderate hypertension, producing sustained 24-h blood pressure control which compared favourably with losartan.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Mallion, J., Siche, J., Lacourcière, Y. et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 13, 657–664 (1999). https://doi.org/10.1038/sj.jhh.1000925
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000925
Keywords
This article is cited by
-
The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases
Drug Safety (2015)
-
A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure
Hypertension Research (2013)
-
Efficacy/Safety of Olmesartan Medoxomil Versus Losartan Potassium in Naïve Versus Previously Treated Subjects With Hypertension
Advances in Therapy (2012)
-
Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy
Hypertension Research (2009)
-
Meta-analysis of Randomized Controlled Trials Comparing Telmisartan With Losartan in the Treatment of Patients With Hypertension
American Journal of Hypertension (2008)